ASX:EX1

Exopharm Competitors

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Exopharm (ASX:EX1) Vs. CHV, DDXS, PREV, TNGN, COM, and MYM

Should you be buying EX1 stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Exopharm, including (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), and 17031 (MYM).

Exopharm vs. (CHV) Stock

(CHV) (CNSX:CHV) and Exopharm (ASX:EX1) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Earnings & Valuation

This table compares (CHV) and Exopharm's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(CHV)	N/A	N/A	N/A	N/A	N/A
Exopharm	$2.72 million	0.00	$-9,758,980.00	A($0.07)	N/A

(CHV) has higher earnings, but lower revenue than Exopharm.

Analyst Ratings

This is a summary of recent recommendations for (CHV) and Exopharm, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(CHV)	0	0	0	0	N/A
Exopharm	0	0	0	0	N/A

Profitability

This table compares (CHV) and Exopharm's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(CHV)	N/A	N/A	N/A
Exopharm	N/A	N/A	N/A

Summary

Exopharm beats (CHV) on 1 of the 1 factors compared between the two stocks.

Exopharm vs. (DDXS) Stock

(DDXS) (OTCMKTS:DDXS) and Exopharm (ASX:EX1) are both health technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares (DDXS) and Exopharm's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(DDXS)	N/A	N/A	N/A	N/A	N/A
Exopharm	$2.72 million	0.00	$-9,758,980.00	A($0.07)	N/A

(DDXS) has higher earnings, but lower revenue than Exopharm.

Analyst Recommendations

This is a breakdown of recent ratings for (DDXS) and Exopharm, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(DDXS)	0	0	0	0	N/A
Exopharm	0	0	0	0	N/A

Profitability

This table compares (DDXS) and Exopharm's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(DDXS)	N/A	N/A	N/A
Exopharm	N/A	N/A	N/A

Summary

Exopharm beats (DDXS) on 1 of the 1 factors compared between the two stocks.

Exopharm vs. (PREV) Stock

(PREV) (CNSX:PREV) and Exopharm (ASX:EX1) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares (PREV) and Exopharm's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(PREV)	N/A	N/A	N/A	N/A	N/A
Exopharm	$2.72 million	0.00	$-9,758,980.00	A($0.07)	N/A

(PREV) has higher earnings, but lower revenue than Exopharm.

Analyst Recommendations

This is a breakdown of recent ratings for (PREV) and Exopharm, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(PREV)	0	0	0	0	N/A
Exopharm	0	0	0	0	N/A

Profitability

This table compares (PREV) and Exopharm's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(PREV)	N/A	N/A	N/A
Exopharm	N/A	N/A	N/A

Summary

Exopharm beats (PREV) on 1 of the 1 factors compared between the two stocks.

Exopharm vs. (TNGN) Stock

(TNGN) (OTCMKTS:TNGN) and Exopharm (ASX:EX1) are both health technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares (TNGN) and Exopharm's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(TNGN)	N/A	N/A	N/A	N/A	N/A
Exopharm	$2.72 million	0.00	$-9,758,980.00	A($0.07)	N/A

(TNGN) has higher earnings, but lower revenue than Exopharm.

Analyst Recommendations

This is a breakdown of recent ratings for (TNGN) and Exopharm, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(TNGN)	0	0	0	0	N/A
Exopharm	0	0	0	0	N/A

Profitability

This table compares (TNGN) and Exopharm's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(TNGN)	N/A	N/A	N/A
Exopharm	N/A	N/A	N/A

Summary

Exopharm beats (TNGN) on 1 of the 1 factors compared between the two stocks.

Exopharm vs. 138267 (COM.TO) Stock

138267 (COM.TO) (TSE:COM) and Exopharm (ASX:EX1) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Earnings and Valuation

This table compares 138267 (COM.TO) and Exopharm's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
138267 (COM.TO)	N/A	N/A	N/A	N/A	N/A
Exopharm	$2.72 million	0.00	$-9,758,980.00	A($0.07)	N/A

138267 (COM.TO) has higher earnings, but lower revenue than Exopharm.

Analyst Recommendations

This is a breakdown of recent ratings for 138267 (COM.TO) and Exopharm, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
138267 (COM.TO)	0	0	0	0	N/A
Exopharm	0	0	0	0	N/A

Profitability

This table compares 138267 (COM.TO) and Exopharm's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
138267 (COM.TO)	N/A	N/A	N/A
Exopharm	N/A	N/A	N/A

Summary

Exopharm beats 138267 (COM.TO) on 1 of the 1 factors compared between the two stocks.

Exopharm vs. 17031 Stock

17031 (CNSX:MYM) and Exopharm (ASX:EX1) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Profitability

This table compares 17031 and Exopharm's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
17031	N/A	N/A	N/A
Exopharm	N/A	N/A	N/A

Earnings and Valuation

This table compares 17031 and Exopharm's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
17031	N/A	N/A	N/A	N/A	N/A
Exopharm	$2.72 million	0.00	$-9,758,980.00	A($0.07)	N/A

17031 has higher earnings, but lower revenue than Exopharm.

Analyst Recommendations

This is a breakdown of recent ratings for 17031 and Exopharm, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
17031	0	0	0	0	N/A
Exopharm	0	0	0	0	N/A

Summary

Exopharm beats 17031 on 1 of the 1 factors compared between the two stocks.